Related Experiment Video
Updated: Dec 2, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication
Yong-Moon Lee1, Man Hwan Oh2, Jai-Hyang Go1
1Department of Pathology, School of Medicine, Dankook University, Cheonan, 31116, Republic of Korea.
Background:
Triple-negative breast cancer (TNBC) is a heterogeneous entity that encompasses several subtypes with distinct molecular characteristics. The patients with TNBCs show unpredictable response to the chemotherapy, and further there is the lack of effective agents. Thus, many studies have been underway to discover targeted therapy suitable for patients with specific genetic alterations in each molecular subtypes. TNBCs are classified as four major molecular subtypes according to the gene expression patterns. These are luminal androgen receptor (LAR), mesenchymal-like, immunomodulatory (IM), and basal-like types.
Conclusion:
Here, we discuss the unique molecular features of each subtype as well as promising targets for anti-cancer therapy.
Insights
Triple-negative breast cancer (TNBC) is diverse, with four subtypes: luminal androgen receptor (LAR), mesenchymal-like, immunomodulatory (IM), and basal-like. Understanding these subtypes is key to developing targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) presents significant heterogeneity.
- TNBC exhibits unpredictable responses to chemotherapy, lacking effective targeted agents.
- Subtyping TNBC is crucial for developing personalized treatment strategies.
Purpose of the Study:
- To elucidate the distinct molecular characteristics of major TNBC subtypes.
- To identify promising therapeutic targets for each molecular subtype.
- To advance the development of precision medicine for TNBC patients.
Main Methods:
- Gene expression profiling to classify TNBC subtypes.
- Comparative analysis of molecular features across subtypes.
- Literature review of potential therapeutic targets.
Main Results:
- TNBC classified into four major molecular subtypes: luminal androgen receptor (LAR), mesenchymal-like, immunomodulatory (IM), and basal-like.
- Each subtype displays unique molecular signatures.
- Specific molecular alterations within subtypes suggest potential therapeutic vulnerabilities.
Conclusions:
- Targeted therapies tailored to specific TNBC molecular subtypes hold promise.
- Further research into subtype-specific molecular features will guide novel treatment development.
- Personalized therapeutic approaches are essential for improving outcomes in TNBC.
